Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valerio Berdini

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Journal of Medicinal Chemistry|December 10, 2016
Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>)Alison J-A Woolford, Philip J Day, Véronique Bénéton, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Structure-Based Design of Type II Inhibitors Applied to Maternal Embryonic Leucine Zipper KinaseChristopher N Johnson, Christophe Adelinet, Valerio Berdini, et al.
ACS Medicinal Chemistry Letters|July 21, 2015
Fragment-Based Discovery of Potent and Selective DDR1/2 InhibitorsChristopher W Murray, Valerio Berdini, Ildiko M Buck, et al.
ACS Chemical Biology|August 30, 2016
Structure of the Epigenetic Oncogene MMSET and Inhibition by N-Alkyl Sinefungin DerivativesDominic Tisi, Elisabetta Chiarparin, Emiliano Tamanini, et al.
Journal of Medicinal Chemistry|January 16, 2009
Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activitySteven Howard, Valerio Berdini, John A Boulstridge, et al.
Journal of Medicinal Chemistry|July 29, 2008
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug designPaul G Wyatt, Andrew J Woodhead, Valerio Berdini, et al.
Molecular Cancer Therapeutics|July 31, 2021
ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERKJoanne M Munck, Valerio Berdini, Luke Bevan, et al.
Journal of Medicinal Chemistry|May 12, 2016
Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Discovered through X-ray Fragment ScreeningAlison J-A Woolford, Joseph E Pero, Sridhar Aravapalli, et al.
Molecular Cancer Therapeutics|July 19, 2011
Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer modelsMatthew Squires, George Ward, Gordan Saxty, et al.
Journal of Medicinal Chemistry|August 13, 2021
Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2Tom D Heightman, Valerio Berdini, Luke Bevan, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Journal of Medicinal Chemistry|December 10, 2016
Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>)Alison J-A Woolford, Philip J Day, Véronique Bénéton, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Structure-Based Design of Type II Inhibitors Applied to Maternal Embryonic Leucine Zipper KinaseChristopher N Johnson, Christophe Adelinet, Valerio Berdini, et al.
ACS Medicinal Chemistry Letters|July 21, 2015
Fragment-Based Discovery of Potent and Selective DDR1/2 InhibitorsChristopher W Murray, Valerio Berdini, Ildiko M Buck, et al.
ACS Chemical Biology|August 30, 2016
Structure of the Epigenetic Oncogene MMSET and Inhibition by N-Alkyl Sinefungin DerivativesDominic Tisi, Elisabetta Chiarparin, Emiliano Tamanini, et al.
Journal of Medicinal Chemistry|January 16, 2009
Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activitySteven Howard, Valerio Berdini, John A Boulstridge, et al.
Journal of Medicinal Chemistry|July 29, 2008
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug designPaul G Wyatt, Andrew J Woodhead, Valerio Berdini, et al.
Molecular Cancer Therapeutics|July 31, 2021
ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERKJoanne M Munck, Valerio Berdini, Luke Bevan, et al.
Journal of Medicinal Chemistry|May 12, 2016
Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Discovered through X-ray Fragment ScreeningAlison J-A Woolford, Joseph E Pero, Sridhar Aravapalli, et al.
Molecular Cancer Therapeutics|July 19, 2011
Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer modelsMatthew Squires, George Ward, Gordan Saxty, et al.
Journal of Medicinal Chemistry|August 13, 2021
Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2Tom D Heightman, Valerio Berdini, Luke Bevan, et al.
Pageof 3